Travere Therapeutics’ $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Pietro Martinoia
Tagged:

Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters.Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of 8,275,000…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Pietro Martinoia

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here